Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Designed Host Defense Peptides for the Treatment of Bacterial Keratitis

Award Number: R43EY024463
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2014
PERIOD OF PERFORMANCE END DATE: 07/31/2016

Group Awards By:

View Award Description

Designed Host Defense Peptides for the Treatment of Bacterial Keratitis - DESCRIPTION (provided by applicant): Bacterial keratitis, due to its potential to cause irreversible blindness, requires prompt intervention. In the United States there are approximately 30,000 patients annually, with contact lens wear being the prime risk factor. Bacterial keratitis i presently treated with antibiotics however innovation in antimicrobial agents and treatment is needed due to the rapid emergence of bacterial resistance and resilience due to biofilm formation. Designed host defense peptides (dHDPs) are derived from naturally occurring HDPs which are ubiquitous in nature and provide the first line of defense against invading pathogens. Aero-Dap LLC has developed novel dHDPs with potent antibacterial activity which may also promote wound healing while concurrently reducing scarring and inflammation and thereby prevent potential blindness in patients with bacterial keratitis. In this proposal, the in vitro cytotoxicity and anti-inflammatory effects of the peptides will be evaluated on corneal epithelial cells and fibroblast cells. Wound healing will be assessed in an in vitro model prior to the lead peptide being evaluated in an in vivo corneal wound model. The antimicrobial efficacy of the lead peptide will be assessed in a keratitis model. If proved successful the compound will undergo the appropriate regulatory- enabling studies with a SBIR grant-funded Phase II study that could lead to a commercially viable therapeutic agent for the treatment of bacterial keratitis


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2017 ( Subtotal = $0 )
2017	2014	RIPTIDE BIOSCIENCE, INC.	941 RAILROAD AVE	VALLEJO	CA	94592	SOLANO	USA	Vision Research	000	1	3/20/2017	NEW	$0
														Subtotal = $0

Issue Date FY: 2014 ( Subtotal = $222,179 )
2014	2014	RIPTIDE BIOSCIENCE, INC.	941 RAILROAD AVE	VALLEJO	CA	94592	SOLANO	USA	Vision Research	000	1	7/23/2014	NEW	$222,179
														Subtotal = $222,179

Grand Total All Awards = $222,179

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Designed Host Defense Peptides for the Treatment of Bacterial Keratitis

Award Number: R43EY024463

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2014

PERIOD OF PERFORMANCE END DATE: 07/31/2016

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer